OptraSCAN has given tissuepathology.com a rare insight into their advisory board discussions as to what their thought leaders think is important in the digital pathology space for the market. OptraSCAN is of course the first On-Demand...

Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current Promega...

I recently had an opportunity to speak with Esther Abels, Director of Regulatory, Clinical and Medical Affairs for Philips Digital Pathology Solutions about Philips’ recent approval to market their Philips Intellisite Pathology System (PIPS)...

Last month the FDA approved pembrolizumab (KEYTRUDA) for adult and pediatric patients with with metastatic or unresectable, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors that have...

Much is being said, written and discussed about the recent FDA clearance for Philips digital pathology solution for primary surgical pathology diagnosis. Of course, this means an advantage for Philips right now in the market as the only FDA...

Thu, May 4th, 2017 11:00 AM EST (1 hour) As a leader in the field, Philips is a driver of the adoption of digital pathology. Our solution was developed with the aim to increase efficiency and collaboration in your clinical lab. We are very...